Core Viewpoint - 加科思药业 has seen significant management confidence through recent share buybacks and purchases, indicating a belief in the undervaluation of the company and its pipeline potential [1][4] Group 1: Shareholder Actions - 加科思药业 announced that its concerted parties have recently increased their holdings by 854,400 shares at an average price of HKD 5.88 per share, totaling over HKD 5 million [1] - The company does not rule out the possibility of further share purchases in the future [1] - The management's high-level purchases reflect a strong belief in the company's value and pipeline confidence, especially after a 427% increase in stock price year-to-date [1] Group 2: Product Pipeline and Market Potential - The company's most notable product, the KRAS inhibitor JAB-23E73, has entered Phase I trials in China and the U.S., with a global sales peak potential of USD 12.1 billion, particularly in pancreatic and non-small cell lung cancers [2] - JAB-23E73 is a small molecule oral drug with promising pharmacokinetics and significant anti-tumor activity, showing a cost advantage over competitors [3] - 加科思's market capitalization is currently at HKD 5 billion, significantly lower than Revolution Medicine's USD 7 billion, indicating substantial upside potential [3] Group 3: Financial Outlook and Revenue Generation - The approval of the KRAS G12C inhibitor, 戈来雷塞, marks a critical milestone for 加科思, expected to generate stable cash flow through its commercialization [4] - 戈来雷塞 is priced at approximately HKD 38,000 per month, with a potential market size of HKD 6 billion based on patient demographics and market share estimates [4] - The strategic partnership with 艾力斯 for sales in China could yield approximately HKD 200 million annually from milestone and sales sharing, providing solid performance support for the company's current valuation [5] Group 4: Future Developments - The SHP2 inhibitor JAB-3312 is the first of its kind to enter Phase III trials, with potential implications for first-line treatment of non-small cell lung cancer, which could trigger additional milestones for 艾力斯 and become a new revenue source [6]

聚焦肿瘤、自体免疫和炎症性疾病领域。 本文为IPO早知道原创 作者｜罗宾 2021年，劲方医药与信达生物（1801.HK）就GFH925达成授权交易，授予信达生物于大中华区开 发及商业化GFH925权益，以及在中国以外的全球地区开发及商业化此款产品的中国境外选择权。 2024年1月，双方签订GFH925补充协议，终止上述协议中的中国境外选择权。 劲方正在推进GFH925的海外临床开发，包括在EMA监管区域内国家进行与cetuximab（一款靶向 EGFR的抗体药物）联用作为一线治疗晚期NSCLC的联合疗法的Ib/II期临床试验。公司认为此款联 合疗法有望在抑制EGFR-RAS通路方面实现协同效应。 劲方医药另一款核心产品GFH312为劲方医药自主研发的高效小分子抑制剂，能针对受体相互作用的 丝氨酸/苏氨酸蛋白激酶1（RIPK1）并抑制其激酶活性， GFH312已获得FDA关于在美国开展第II 期临床试验的IND批准 ，以评估GFH312对外周动脉疾病（PAD）伴间歇性跛行（IC）患者的安全 性和疗效。与全球其他临床阶段的RIPK1抑制剂相比，劲方医药聚焦 GFH312的差异化临床计划， 针对一些可能严重影响患 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統 稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發 展的資料。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1167） 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司自主研發的泛KRAS抑制劑 JAB-23E73在中國完成I/IIa期臨床試驗首例患者給藥。 KRAS廣泛存在於多種腫瘤突變，約23%-25%的癌症患者帶有KRAS突變，全球 每年新增約270萬帶有KRAS相關突變的腫瘤患者有望從泛KRAS抑制劑中獲益。 自願公告 加科思完成泛KRAS抑制劑JAB-23E73 I/IIa期 臨牀試驗在中國的首例患者給藥 承董事會命 加科思藥業集團有限公司 董事長 王印祥 香港，2024年11月25日 ...